Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Report Date: April 2, 2026
Context: This filing serves as a cover document for a press release dated April 2, 2026 (Exhibit 99.1). The registrant is a French biopharmaceutical company headquartered in Marseille.
Key Financial Metrics
The provided filing text contains only the cover page and signature block for Form 6-K. It does not include the content of the referenced press release or any financial statements. Consequently, the filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material changes versus the prior comparable period can be identified from the provided text, as no financial data or operational updates are included in the excerpt.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or details regarding unusual items. These details are presumably contained within the attached Exhibit 99.1 (Press Release), which is not included in the input content.
Investor Verification Checklist
- Verify the full content of the Press Release dated April 2, 2026 (Exhibit 99.1) to understand the specific announcement triggering this filing.
- Confirm whether the press release contains updated clinical trial data, regulatory milestones, or financial results.
- Review the company's most recent Form 20-F for the latest audited financial position, as this 6-K does not provide current financial metrics.